4/14, 3:42 PM (Source: TeleTrader)
more TeleTrader news

EMA checking if regulatory action is needed on J&J jab

The European Medicines Agency (EMA) confirmed on Wednesday it was still investigating the potential connection between blood clots and Johnson and Johnson's (J&J) vaccine against COVID-19, after which it would decide "whether regulatory action is necessary."

"EMA is expediting this evaluation and currently expects to issue a recommendation next week. While its review is ongoing, EMA remains of the view that the benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects," it stated. EMA approved the vaccine on March 11; however, its widespread use in the European Union has not started yet.

The EMA decided to review possible side effects the jab might lead to after the United States Food and Drug Administration (FDA) paused its use over concerns it caused blood clots.

Breaking the News / JR